NEW YORK (GenomeWeb News) — Eurofins said today that its Panlabs pharmacology services arm has signed an agreement with GE Healthcare giving it the exclusive right to offer GE's Cytiva cardiomyocytes for cardiotoxicity screening services.

Cardiomyocytes offer a cost-effective and time-efficient alternative to animal models for predictive cardiotoxicity testing in drug discovery and development, Eurofins said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.